Cargando...
Progression-free survival/time to progression as a potential surrogate for overall survival in HR+, HER2− metastatic breast cancer
BACKGROUND: Several recent randomized controlled trials (RCTs) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (MBC) have demonstrated significant improvements in progression-free survival (PFS); however, few have reported improv...
Gardado en:
| Publicado en: | Breast Cancer (Dove Med Press) |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5942170/ https://ncbi.nlm.nih.gov/pubmed/29765247 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BCTT.S162841 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|